NCI’s Office of Cancer Clinical Proteomics Research serves as the NCI Representative/Project Team Leader to this NIH Common Fund program. The NIH Common Fund’s Protein Capture Reagents program is developing affinity-based renewable resources to empower the research community. The affinity-based reagents will enable researchers to better understand the critical role cellular proteins play in normal development and health as well as in disease (http://commonfund.nih.gov/proteincapture). For more information about the Common Fund visit http://commonfund.nih.gov.
The NIH Common Fund’s Illuminating the Druggable Genome program goal is to increase the understanding of the properties and functions of poorly understood proteins within four of the most commonly drug-targeted protein families, the G-protein coupled receptors (GPCRs), nuclear receptors (NRs), ion channels, and protein kinases. By Illuminating the Druggable Genome a focus will be turned on the “dark matter” of the Druggable Genome through deep annotation to establish function and potential role in disease. By expanding the scope of the potential druggable genome through deep understanding of underlying biology, the therapeutics discovery pipeline can be energized and new scientific pathways for understanding function and role in disease revealed. IDG seeks to begin by expanding the knowledge base of the Druggable Genome to allow for in silico discovery and prioritization of paths to follow with detailed annotation studies. Parallel efforts to adapt and scale assays for rapid and high throughput annotation will constitute a second arm of IDG. Together the two arms will synergize and collaborate through formation of a consortium to bring investigators from different disciplines together and address these difficult but important problems. Ultimately, the goal of the program is to foster basic research by accumulating genomic data to inform our knowledge of the proteome enabling small businesses and the pharmaceutical industry with the ability to design novel therapeutics (http://commonfund.nih.gov/idg). NCI’s Office of Cancer Clinical Proteomics Research serves as the NCI Representative/Project Scientist to this NIH Common Fund program. For more information about the Common Fund visit http://commonfund.nih.gov.
The National Institutes of Health has recently awarded additional grants as part of GTEx project to explore how human genes are expressed and regulated in different tissues, and the role that genomic variation plays in modulating that expression. The GTEx awards will contribute to a resource database and tissue bank that researchers can use to study how inherited genomic variants may influence gene activity and lead to disease. Recent awards include a project which aims to characterize the many different ways in which proteins normally vary across multiple tissue types. Scientists will catalog protein variants by mass spectrometry, which will help them understand the genetic basis for protein variation. This will be a valuable resource for researchers to understand the genetic basis of complex traits, and ultimately, in predicting individual disease susceptibility. These research results may also help clinicians design individual prevention and treatment strategies. NCI’s Office of Cancer Clinical Proteomics Research and GTEx Common Fund Office coordinate their efforts to maximize deliverables of such projects. (https://commonfund.nih.gov/GTEx). For more information about the Common Fund visit http://commonfund.nih.gov.